ADP-A2M10

Overview

Overview

Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors.

Please note that the two trials with ADP-A2M10 are now closed for enrollment.

Our Trials

pipeline

Cancer indications in the ADP-A2M10 trials

Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer or NSCLC is the most common type of lung cancer, representing about 85% of lung cancers.

Urothelial

Urothelial

Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is the most common type of bladder cancer.

Melanoma

Melanoma

Melanoma is a cancer that begins in specific skin cells called melanocytes.

Head and Neck

Head and Neck

Head and neck cancer arises in the epithelium of the paranasal sinuses, nasopharynx, oropharynx, oral cavity, hypopharynx and larynx.

Publications

Review our findings and publications.

Latest News

Focusing efforts on ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP, with enrollment in the ADP‑A2M10 trials closing by the end of 2019

View Press Release